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Abstract 
 
Purpose 
Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The 
prognosis is poor, and although radiotherapy (RT), systemic and intra-thecal (IT) chemotherapy are 
accepted treatment modalities, efficacy data are limited. This study was designed to evaluate 
potential predictors of survival in this patient group. 
 
Methods  
Breast cancer patients with LMD diagnosed by MRI in a 10-year period (2004-2014) were identified 
from electronic patient records. PFS and OS estimates were calculated using Kaplan-Meier method, 
with planned sub-group analysis by treatment modality. Cox regression was employed to identify 
significant prognostic variables. 
 
Results 
We identified 182 eligible patients; all female, median age at LMD diagnosis 52.5 years (range 23-
80). Ninety patients (49.5%) were ER positive/HER2 negative; 48 (26.4%) were HER2 positive, and 27 
(14.8%) were triple negative. HER2 status was unknown in 17 (9.3%). Initial management of LMD 
was most commonly whole or partial brain RT in 62 (34.1%), systemic therapy in 45 (24.7%) or 
supportive care alone in 37 (20.3%). Fourteen patients (7.7%) underwent IT chemotherapy, of whom 
two also received IT trastuzumab.  
From diagnosis of LMD, the median PFS was 3.9 months (95%CI 3.2-5.0) and median OS was 5.4 
months (95%CI 4.2-6.6). Patients treated with systemic therapy had the longest OS (median 8.8 
months, 95%CI 5.5-11.1), compared to RT; 6.1 months (95%CI 4.2-7.9 months), IT therapy; 2.9 
months (95%CI 1.2-5.8) and supportive care; 1.7 months (95%CI 0.9-3.0). On multivariable analysis, 
triple negative histology, concomitant brain metastases, and LMD involving both the brain and spinal 
cord were associated with poor OS. 
 
Conclusions 
Breast cancer patients with triple negative LMD, concomitant brain metastases or LMD affecting 
both the spine and brain have the poorest prognosis. Clinical trials to identify more effective 
treatments for these patients are urgently needed. 
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Introduction 
 
Metastatic cancer affecting the meninges, or leptomeningeal disease (LMD), is an uncommon 
complication of advanced breast cancer (ABC). Previously estimated to occur in 5% of ABC 
patients[1], the prevalence is thought to be increasing due to increased diagnostic accuracy and 
longer survival in breast cancer. Usually this is a late complication of ABC, but rarely it can be a 
presenting feature[2,3]. Symptoms of LMD vary according to the affected site, for example motor or 
sensory symptoms may occur from LMD affecting the meninges around the spinal cord or cauda 
equina, and headache, nausea and seizures can occur secondary to raised intracranial pressure from 
obstructive hydrocephalus. Diagnosis is normally made by MRI scan with gadolinium contrast, 
sometimes confirmed by cytological evaluation of cerebro-spinal fluid (CSF). As the sensitivity of CSF 
cytology is low[4], CSF examination for other biochemical markers such as CA15-3 have been 
investigated[5], but have not reached routine clinical practice.  The mechanism of LMD development 
is not well understood, but it appears to occur via direct extension through the dura from spinal or 
skull bony metastases in most patients[6], and via haematogenous spread, sometimes in association 
with parenchymal brain metastases in others.  The optimal management strategy for LMD remains 
unclear, and may differ according to the affected site, extent of disease and resulting symptoms.  
 
Triple negative disease and HER2 positive disease are associated with a higher risk of developing 
parenchymal brain metastases than luminal breast cancer[7], but the risk factors for developing LMD 
are less clearly defined.  An Italian cohort study identified both ER negative and HER2 positive as risk 
factors for developing LMD, as well as grade 3 tumours, young age, primary tumours >15mm and the 
involvement of 3 or more lymph nodes at breast cancer diagnosis [8]. Other retrospective studies 
have noted over representation of triple negative breast cancer and lobular histology [9–11]. 
 
Our study aimed to determine whether clinical outcomes from LMD varied with differing 
management strategies and to detect prognostic factors by studying the demographics and survival 
of all patients diagnosed with LMD within one UK breast oncology unit over a 10-year period. 
Identifying those at higher risk of developing the disease may then highlight areas for further 
research and direct future clinical trials.  
 
Methods 
 
Study Population 
 
The study population included patients with a diagnosis of breast cancer and LMD treated at The 
Royal Marsden Hospital.  Eligible patients were identified by searching reports from all MRI scans 
performed on breast cancer patients between January 2004 and January 2014 for the term 
“meningeal”. All MRI reports were verified by a Consultant Radiologist. MRI reports were manually 
checked for positive findings which were subsequently crosschecked against the notes for a clinical 
diagnosis. Those with suggestive radiological imaging and a clinical diagnosis of LMD were the 
included in the study. Due to the low sensitivity of CSF examination[12], this was not required to 
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make the diagnosis. The results were cross-checked with pharmacy records of breast cancer patients 
treated with intrathecal (IT) chemotherapy or trastuzumab.  
Hormone receptor positive was defined as an oestrogen and/or progesterone receptor Allred score 
of 3/8 or greater.  HER2 positive was defined as HER2 3+ positive by IHC, or an in situ hybridisation 
(ISH) ratio >2.0, or an absolute HER2 copy number of ≥ 6 also defined HER2 positivity regardless of 
ratio, as per ASCO/CAP guidelines[13]. 
 
Data Collection 
 
The electronic patient record (EPR) was scrutinised for patient demographics; dates of diagnosis of 
early breast cancer, metastatic cancer, and LMD; grade of initial breast cancer, hormone and HER2 
receptor status; sites of metastatic disease; sites of LMD (brain, spinal or both); symptoms at 
presentation of LMD; presence or absence of concomitant brain metastases, presence of skull bone 
or spinal metastasis; CSF cytology, protein and glucose findings; initial and subsequent management 
(palliative, systemic therapy, intrathecal (IT) chemotherapy, radiotherapy) of the LMD; outcome of 
treatment; date of death or last follow up.  
 
Statistical Analysis 
 
The primary endpoint of the study was the overall survival (OS) from date of diagnosis of LMD, to 
date of death from any cause, according to treatment received (radiotherapy, intrathecal treatment, 
systemic treatment versus supportive care only). 
 
Secondary endpoints comprised of progression-free survival (PFS) from LMD diagnosis (date of 
diagnosis of LMD to date of imaging, clinical or CSF progression or death) by treatment modality; the 
frequency of different sub-types of breast cancer in patients with LMD; the proportion of patients 
who have prior or synchronous parenchymal brain metastasis at time of diagnosis of LMD; the 
proportion of patients who had skull bone or spinal bony disease prior to diagnosis of LMD; 
Response rate to treatment received as determined by change from CSF positive to negative 
cytology and/or resolution of leptomeningeal enhancement on MRI and/or resolution of 
neurological signs; and to determine whether any demographics or tumour characteristics predict 
survival from LMD.  
 
Data were analysed using means and percentages for demographic data, clinico-pathological 
features, disease sites, symptoms, management, and response rate. PFS and OS estimates were 
calculated using Kaplan-Meier method, with planned sub-group analysis by treatment modality. Cox 
regression was employed to identify significant prognostic variables. P values of less than 0.05 were 
considered significant.  
 
Results 
 
Patients  
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We identified 182 eligible patients over the 10-year period: baseline characteristics are summarised 
in Table 1. The mean age at diagnosis of breast cancer was 47.7 years (range 19-75); younger than 
the average age of breast cancer diagnosis in the UK of 64 years[14]. Hormone receptor positive 
(HR+) and HER2 negative tumours were the largest sub-group (49.5%).  Triple negative disease 
accounted for 14.8% of cases.  HER2 positive disease was marginally more common in our LMD 
cohort (26%) than expected in the overall breast cancer population, estimated at around 10-15% 
[15] and HER2 status was unknown in a further 9.3%. Over half of patients (55.0%) had grade 3 
primary tumours.  
 
A third of the patients presented with multiple symptoms (59 patients, 32.4%). The most frequent 
solitary presenting symptoms were headache (40 patients, 22%) and cranial nerve palsy (17 patients, 
9.2%). 
 
At diagnosis of LMD, the majority of patients (73.6%) had concomitant skull bone or spinal bone 
disease, and 50% had pre-existing or concomitant intra-parenchymal brain disease. Interestingly, 
13% had neither bone nor parenchymal brain metastases. Of this subgroup of patients, 35% had 
triple negative breast cancer, and 70% had grade 3 breast cancer at the time of diagnosis.  
 
Few patients (n=19) underwent lumbar puncture for cytological confirmation, of whom 10 (52.6%) 
had positive cytology.  
 
Treatment of LMD 
 
The initial management strategy varied across this cohort of patients (summarised in Table 2). 
Treatment strategy was dependent on the patient’s symptoms, performance status, systemic 
disease control, and patient and physician choice. The most frequent initial treatment for LMD was 
whole or partial brain radiotherapy (62 patients, 34.1%). One third of the patients who received RT 
as treatment for LMD also continued to receive their prior systemic therapy with chemotherapy 
(25), trastuzumab (3), or endocrine therapy (2). 
Systemic chemotherapy was given as the initial treatment for LMD in 45 patients (24.7%), with a 
median of 4 cycles.  The commonest therapy was capecitabine (21 patients, 46.7% of all patients 
receiving systemic therapy). Other systemic therapies included platinum salts (15.6%), taxanes 
(13.3%) anthracyclines (6.7%), T-DM1 (2.2%), eribulin (2.2%), vinorelbine (2.2%), and hormonal 
agents (6.7%). Six of the 21 patients receiving capecitabine additionally received targeted anti-HER2 
therapy with lapatinib (5) or trastuzumab (1). 
A supportive (palliative) care strategy was adopted in 44 patients (20.3%) for the LMD. Of these 
patients, 6 patients (13.6%) continued capecitabine (3) or hormonal therapy (3) for clinical benefit at 
other disease sites.  Eight patients later underwent subsequent active treatment with chemotherapy 
(3 patients, 6.8%), or radiotherapy (5 patients, 9.1%). 
Of the 14 patients receiving intrathecal chemotherapy as their first line treatment after diagnosis of 
LMD, 7 received IT methotrexate monotherapy (12.5mg weekly), 2 received methotrexate (12.5mg) 
plus hydrocortisone (12.5mg), 3 received IT methotrexate (12.5mg) combined with cytarabine 
(50mg) and hydrocortisone (12.5mg) and 2 patients received intrathecal methotrexate (12.5mg) 
with trastuzumab (test dose 40mg, then 105mg weekly). Four of the 14 patients (28.6%) received 
concomitant systemic chemotherapy (1 with trastuzumab, 1 with trastuzumab and pertuzumab, 2 
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with endocrine therapy) and 1 patient received spinal RT (8Gy) whilst awaiting IT treatment. Clinical 
symptoms improved in 4 of the 14 patients (28.6%) who received intrathecal treatment. Two of 
these patients showed a concomitant cytological and imaging response in addition to the clinical 
response.  
 
Survival 
 
The median PFS in all patients was 3.9 months (95% CI 3.2-5.0), median OS 5.4 months (95% CI 4.2-
6.6). The longest median PFS and OS were observed in patients selected to receive initial systemic 
chemotherapy (5.3 and 8.8 months respectively; table 3). Amongst the fourteen patients who 
received first line IT chemotherapy the median PFS and OS were similar to that for supportive care 
alone: 2.4 and 2.9 months respectively compared to 1.3 and 1.7 months respectively for supportive 
care. However, one of the two patients who received IT trastuzumab with methotrexate is still alive 
and receiving on-going treatment with 3-weekly trastuzumab (21mg) via an Omaya reservoir plus 
sub-cutaneous trastuzumab more than 2 years after diagnosis of LMD. The second patient who 
received IT trastuzumab progressed at 4 weeks and died at 8 weeks. Amongst the 12 patients who 
received IT chemotherapy alone, 4 had symptomatic benefit. Two of these patients survived for 18 
and 26 months, respectively. Figure 1 illustrates the PFS and OS by treatment groups. 
 
 
Prognostic factors 
 
On multivariate analysis, older age at diagnosis of LMD, triple negative sub-type, prior or 
concomitant brain metastases, presence of brain and spinal LMD, and low albumin level at LMD 
diagnosis were predictive of poorer prognosis (Table 4).  
 
Discussion 
 
We report the treatment and outcomes of 182 breast cancer patients diagnosed with 
leptomeningeal disease over a 10-year period in one single centre in the United Kingdom. Our study 
confirms that patients presenting with LMD have a poor prognosis, with a median OS of just 5.4 
months (95% C.I 4.3 – 6.6). Our survival results are similar to two large cohort studies reported from 
centres in the USA, with median OS of 3.5 months and 3.1 months, respectively[16,17]. Intrathecal 
treatment was uncommon in our study (7.7% of patients), compared to 50% of patients reported in 
the study from the MD Anderson[17] and 14% of patients in the Memorial Sloan Kettering Cancer 
Centre study[16], demonstrating the lack of a standard approach for this disease site. Amongst the 
14 patients in our study treated with IT therapy, the outcome was poor, with a median OS of just 2.9 
months (95% C.I. 1.2-5.8), similar to that with palliative care alone (1.7 months (95% CI 0.9-3.0)). 
There are few randomised studies of IT treatment in LMD in any cancer type[18], and the single 
randomised trial in breast cancer assessed IT methotrexate monotherapy[19], with systemic 
chemotherapy and radiotherapy permitted in both arms. No benefit was reported from the addition 
of IT methotrexate to standard treatment in 35 randomised patients; median OS was numerically 
shorter in patients randomised to IT chemotherapy (median 18.3 compared to 30.3 weeks), but the 
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study was underpowered to detect a difference (p=0.32). It is notable that we had one HER2 positive 
patient who received IT methotrexate with trastuzumab who is still alive and has been free of 
symptoms for more than 2 years post LMD diagnosis[20]. The use of intrathecal trastuzumab has 
been reported in case studies, summarised in a pooled analysis published in 2013[21]. In this series, 
clinically significant improvement was seen in 68.8% of the 17 patients included, with no reports of 
serious events in 88.2% of the patients[21]. A prospective trial of IT trastuzumab for carcinomatous 
meningitis is underway in France (NCT01373710). The study plans to recruit 37 patients and the 
primary endpoint is to establish the maximum tolerated dose (MTD) of weekly IT trastuzumab. 
Interestingly, a USA study of IT anti-HER2 monoclonal antibodies will investigate the combination of 
pertuzumab and trastuzumab, but in patients with asymptomatic/minimally symptomatic brain 
metastases (NCT 02598427), with the primary endpoints of safety and MTD. 
 
Radiotherapy was the most commonly used treatment, both in our study (43%) and the two USA 
cohort studies (75% and 64% respectively). We did not compare the survival outcome of the 
different treatment groups due to the inherent bias in choice of treatment modality, related to 
disease factors such as the site and bulk of the LMD and other sites of disease requiring treatment 
(for example patient factors such as patient wishes, symptom severity, co-morbidities, and 
performance status). There are no clinical trials of radiotherapy for LMD secondary to breast cancer, 
most likely as this treatment is delivered to symptomatic patients with palliative intent, therefore it 
would seem unethical to randomise patient to not receive this palliative treatment. A single arm 
study combining involved-field radiotherapy with intrathecal chemotherapy in patients with LMD 
from any solid tumour (n=59, of whom 11 had breast cancer) reported an 86.4% response rate and 
median OS of 6.5 months, but significant toxicity (grade 3-5 in 12 of 59 patients)[22]. 
 
Systemic therapy in our study comprised standard breast cancer cytotoxic agents, most commonly 
capecitabine. Other cytotoxics such as Temozolamide have been investigated for LMD due to known 
CNS penetration and efficacy in primary brain malignancies[23]; a phase II study of patients with 
LMD from any solid tumour, which was breast cancer in 53% reported that although the treatment 
was well-tolerated, clinical benefit was only reported in 3/19 patients (15.8%)[24].The results of 
small studies of pemetrexed[25] and patupilone[26] have been similarly disappointing. Perhaps 
more promising, a triplet regimen of cisplatin, etoposide and bevacizumab was investigated in 8 
patients with breast cancer LMD and reported objective response in 3 of 5 evaluable patients, 
median PFS 4.7 months (95% CI 0.3-9 months). However, haematological toxicity and hyponatraemia 
were common [27]. As such, there is no current indication to deviate from standard breast cancer 
regimens when treating this site of metastatic disease.  Current studies of systemic therapies for 
breast cancer LMD include a phase II study of high dose (8g/m2) systemic methotrexate (NCT 
02422641), a phase I study of intermittent high dose lapatinib with capecitabine (NCT02650752) and 
a phase II study of the CDK4/6 inhibitor abemaciclib (NCT02308020).  
 
Concordant with previous studies[11,16,17,28], we report that LMD with triple negative histology 
was associated with poorer prognosis. We have also confirmed previous reports that older age[17], 
or having both cranial and spinal involvement[16] were independently associated with a poorer 
prognosis. We have additionally demonstrated that prior or concomitantly diagnosed brain 
metastases, and low albumin level at LMD diagnosis were also independently associated with poorer 
prognosis. Good performance status has been previously reported as a positive predictor of 
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outcome in LMD[4,9,28–30],but we were unable to assess the impact of this parameter in our study 
due to missing documentation. The use of systemic therapy was also associated with improved 
outcome in some retrospective studies[9,17,29,30], with independent benefit from IT chemo or RT 
also reported in one[31].  
 
In conclusion, our study confirms previous reports that LMD carries a poor prognosis in ABC. Triple 
negative disease, older age, extent of LMD, presence of brain metastases and low albumin were 
predictors of shorter survival. Patients who received systemic chemotherapy or radiotherapy had a 
numerically longer median survival than those who received IT chemotherapy or palliative care 
alone, but the retrospective nature of this study limits the interpretation of these results. 
Prospective clinical trials, especially in the poor prognosis groups, are urgently needed in order to 
establish the optimal treatment and improve the outcome for these patients. 
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Table 1: Patient Characteristics 
 Value (%) 
Mean age at Breast cancer diagnosis/years (range) 46.7 years (19-75) 
Histological subtype IDC 153 (84.1) 
ILC 18 (9.9) 
Other 3 (1.6) 
Unknown 8 (4.4) 
Immunohistochemistry HR+HER2- 90 (49.5) 
HER2+ 48 (26.4) 
Triple Negative 27 (14.8) 
HER2 Unknown 17 (9.3) 
Tumour grade of primary 
breast tumour at diagnosis of 
early breast cancer 
1 1 (0.55) 
2 61 (33.5) 
3 100 (55.0) 
 Unknown 20 (11.0) 
Skull bone or spinal disease 
prior or simultaneous to LMD 
diagnosis? 
Yes 134 (73.6) 
No 47 (25.8) 
Unknown 1 (0.5) 
Parenchymal brain 
metastases prior to/at time 
of LMD diagnosis? 
Yes 91 (50.0) 
No 87 (47.8) 
Unknown 4 (2.2) 
CSF Cytology  Positive 10 (5.49) 
Negative 9 (4.94) 
Not performed 163 (89.56) 
Sites of LMD involvement Brain 123 (67.6) 
Spine 36 (19.8) 
Brain and Spine 23 (12.6) 
Symptoms at diagnosis of 
LMD 
Multiple symptoms 59 (32.4) 
Headache 40 (22.0) 
Cranial Nerve palsy 17 (9.3) 
Pure motor 
symptoms 
14 (7.7) 
Visual Changes 12 (6.6) 
Pure sensory 
symptoms 
11 (6.0) 
Asymptomatic 10 (5.5) 
Nausea 5 (2.8) 
Seizure 5 (2.8) 
Pain 5 (2.8) 
Confusion 2 (1.1) 
Cerebellar 
Symptoms 
1 (0.6) 
Diabetes Insipidus 1 (0.6) 
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IDC: Invasive ductal cancer; ILD: Invasive lobular cancer; HR+: Hormone receptor positive; HER2+: 
HER2 receptor positive; HER2-: HER2 receptor negative 
 
Table 2. Initial management of leptomeningeal disease. 
Management Number (%) 
Whole or partial brain RT 62 (34.1) 
Systemic therapy 45 (24.7) 
Supportive care 44 (24.2)* 
RT to skull base or spine 16 (8.8) 
IT chemotherapy 14 (7.7) 
Surgery and stereotactic RT 1 (0.55) 
*8 of the 44 patients initially receiving supportive care only later received active treatment; RT in 5, 
systemic chemotherapy in 3. 
 
 
 
 
Table 3. Survival outcomes (median PFS and OS) in all patients and by 
treatment group. 
 
LMD Treatment PFS (months) (95% C.I.) OS (months) (95% C.I.) 
Any 3.9 (3.2-5.0) 5.4 (4.2-6.6) 
IT chemotherapy 2.4 (1.1-4.1) 2.9 (1.2-5.8) 
Supportive Care 1.3 (0.8-2.1) 1.7 (0.9-3.0) 
Radiotherapy* 5.8 (4.2-7.3) 6.1 (4.2-7.9) 
Systemic therapy 5.3 (3.2-7.4) 8.8 (5.5-11.1) 
*Whole brain radiotherapy, partial brain radiotherapy, spinal radiotherapy and stereotactic 
radiotherapy have been combined. 
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Table 4 Multivariable analysis 
 
Characteristic Hazard Ratio 
(95% C.I) 
P value 
Age at diagnosis Continuous 1.02 (1.00-1.03) 0.029 
Histological Subtype ER+ HER2-  Reference category 
0.007 
ER+ +/- PR+ HER2+ 0.82 (0.51-1.33) 
ER- HER2+ 1.61 (0.85-3.04) 
Triple negative 2.08 (1.24-3.46) 
Concomitant or prior 
skull bone or spinal 
metastases 
No (reference 
category) 
Reference category 
0.356 Yes 0.85 (0.60-1.20) 
Concomitant or prior 
brain metastases 
No (reference 
category) 
Reference category 
0.006 Yes 1.74 (1.17-2.57) 
Location of LMD Brain Only Reference category 
<0.001 
Both 2.81 (1.65-4.80) 
Spine only 1.27 (0.81-1.99) 
Albumin at LMD 
diagnosis 
Continuous 0.97 (0.93-1.0) 0.049 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
Figure 1.A . Progression-free and B. Overall survival by treatment type 
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